CG Oncology (CGON) Expected to Announce Quarterly Earnings on Thursday

Key Points

• CG Oncology is set to report Q1 2026 results before the open on May 7, with analysts forecasting ($0.58) EPS and about $0.453M in revenue; the company’s earnings call is scheduled for May 8 at 12:30 PM ET.
• The stock opened near $64.75 with a 52-week range of $21.00–$73.56 and a market cap of $5.70 billion, and analysts rate it an average of Moderate Buy with a consensus price target of $79.55.
• Director James Mulay sold 15,600 shares at about $73.01 on April 17, reducing his position by 50%, while corporate insiders collectively own roughly 7.4% of the company.

CG Oncology (NASDAQ:CGON - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.58) per share and revenue of $0.4530 million for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 8, 2026 at 12:30 PM ET.

CG Oncology (NASDAQ:CGON - Get Free Report) last released its earnings results on Friday, February 27th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.61) by $0.10. The company had revenue of $2.32 million for the quarter. On average, analysts expect CG Oncology to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CG Oncology Stock Performance

NASDAQ:CGON opened at $64.75 on Thursday. CG Oncology has a fifty-two week low of $21.00 and a fifty-two week high of $73.56. The company has a market cap of $5.70 billion, a price-to-earnings ratio of -31.28 and a beta of 0.70. The stock has a fifty day moving average price of $64.85 and a 200-day moving average price of $52.09.

Analysts Set New Price Targets

Several research analysts have commented on the stock. The Goldman Sachs Group restated a "buy" rating and set a $82.00 price objective on shares of CG Oncology in a research report on Monday, January 12th. Weiss Ratings restated a "sell (d-)" rating on shares of CG Oncology in a research report on Monday, April 20th. Wall Street Zen downgraded shares of CG Oncology from a "hold" rating to a "sell" rating in a research report on Saturday, April 25th. Royal Bank Of Canada boosted their price objective on shares of CG Oncology from $73.00 to $79.00 and gave the company an "outperform" rating in a research report on Monday. Finally, Truist Financial boosted their price objective on shares of CG Oncology from $66.00 to $75.00 and gave the company a "buy" rating in a research report on Tuesday, February 10th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $79.55.

Insider Transactions at CG Oncology

In related news, Director James Mulay sold 15,600 shares of the company's stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the completion of the transaction, the director directly owned 15,600 shares in the company, valued at $1,138,956. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CG Oncology

Hedge funds have recently modified their holdings of the company. Picton Mahoney Asset Management acquired a new stake in shares of CG Oncology during the 4th quarter valued at $118,000. Verition Fund Management LLC bought a new stake in shares of CG Oncology during the third quarter worth about $221,000. CIBC Bancorp USA Inc. bought a new stake in shares of CG Oncology during the third quarter worth about $240,000. Russell Investments Group Ltd. grew its holdings in shares of CG Oncology by 1,180.1% during the third quarter. Russell Investments Group Ltd. now owns 6,119 shares of the company's stock worth $246,000 after purchasing an additional 5,641 shares during the last quarter. Finally, LPL Financial LLC grew its holdings in shares of CG Oncology by 9.8% during the fourth quarter. LPL Financial LLC now owns 6,201 shares of the company's stock worth $257,000 after purchasing an additional 551 shares during the last quarter. Institutional investors and hedge funds own 26.56% of the company's stock.

About CG Oncology

CG Oncology, Inc NASDAQ: CGON is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.